Literature DB >> 19338375

Molecular targets for tumor radiosensitization.

Philip J Tofilon1, Kevin Camphausen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19338375      PMCID： PMC3407885          DOI： 10.1021/cr800504x

Source DB:  PubMed          Journal:  Chem Rev        ISSN： 0009-2665            Impact factor:   60.622


× No keyword cloud information.
  175 in total

Review 1.  Double-strand breaks and tumorigenesis.

Authors:  A J Pierce; J M Stark; F D Araujo; M E Moynahan; M Berwick; M Jasin
Journal:  Trends Cell Biol       Date:  2001-11       Impact factor: 20.808

2.  Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells.

Authors:  Joseph N Contessa; Jaime Hampton; Guido Lammering; Ross B Mikkelsen; Paul Dent; Kristoffer Valerie; Rupert K Schmidt-Ullrich
Journal:  Oncogene       Date:  2002-06-06       Impact factor: 9.867

3.  The Ras radiation resistance pathway.

Authors:  A K Gupta; V J Bakanauskas; G J Cerniglia; Y Cheng; E J Bernhard; R J Muschel; W G McKenna
Journal:  Cancer Res       Date:  2001-05-15       Impact factor: 12.701

4.  Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation.

Authors:  Caroline Delmas; Christophe Heliez; Elizabeth Cohen-Jonathan; Dave End; Jacques Bonnet; Gilles Favre; Christine Toulas
Journal:  Int J Cancer       Date:  2002-07-01       Impact factor: 7.396

5.  Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization.

Authors:  G Lammering; T H Hewit; W T Hawkins; J N Contessa; D B Reardon; P S Lin; K Valerie; P Dent; R B Mikkelsen; R K Schmidt-Ullrich
Journal:  J Natl Cancer Inst       Date:  2001-06-20       Impact factor: 13.506

6.  Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response.

Authors:  Robert J Griffin; Brent W Williams; Robert Wild; Julie M Cherrington; Heonjoo Park; Chang W Song
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

7.  A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer.

Authors:  Stephen M Hahn; Eric J Bernhard; William Regine; Mohammed Mohiuddin; Daniel G Haller; James P Stevenson; Debbie Smith; Barnali Pramanik; Joel Tepper; Thomas F DeLaney; Krystina D Kiel; Briggs Morrison; Paul Deutsch; Ruth J Muschel; W Gillies McKenna
Journal:  Clin Cancer Res       Date:  2002-05       Impact factor: 12.531

Review 8.  Blocking oncogenic Ras signaling for cancer therapy.

Authors:  A A Adjei
Journal:  J Natl Cancer Inst       Date:  2001-07-18       Impact factor: 13.506

9.  Inhibition of radiation-induced nuclear factor-kappaB activation by an anti-Ras single-chain antibody fragment: lack of involvement in radiosensitization.

Authors:  Jeffery S Russell; Uma Raju; Glenice J Gumin; Fredrick F Lang; Deborah R Wilson; Thierry Huet; Philip J Tofilon
Journal:  Cancer Res       Date:  2002-04-15       Impact factor: 12.701

Review 10.  Hsp90: a specialized but essential protein-folding tool.

Authors:  J C Young; I Moarefi; F U Hartl
Journal:  J Cell Biol       Date:  2001-07-23       Impact factor: 10.539
View more
  18 in total

1.  Radiosensitization effect of poly(ADP-ribose) polymerase inhibition in cells exposed to low and high liner energy transfer radiation.

Authors:  Takahisa Hirai; Hidenori Shirai; Hiroaki Fujimori; Ryuichi Okayasu; Keisuke Sasai; Mitsuko Masutani
Journal:  Cancer Sci       Date:  2012-04-19       Impact factor: 6.716

Review 2.  Targeting inflammatory pathways for tumor radiosensitization.

Authors:  Amit Deorukhkar; Sunil Krishnan
Journal:  Biochem Pharmacol       Date:  2010-06-30       Impact factor: 5.858

3.  Cyclophilin B expression is associated with in vitro radioresistance and clinical outcome after radiotherapy.

Authors:  Paul D Williams; Charles R Owens; Jaroslaw Dziegielewski; Christopher A Moskaluk; Paul W Read; James M Larner; Michael D Story; William A Brock; Sally A Amundson; Jae K Lee; Dan Theodorescu
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

4.  Combination therapy of Doxorubicin with TTFields and radiation: newer approaches to combat lung cancer.

Authors:  Won Seok Lee; Eun Ho Kim
Journal:  Am J Cancer Res       Date:  2022-06-15       Impact factor: 5.942

5.  ErbB2, FoxM1 and 14-3-3ζ prime breast cancer cells for invasion in response to ionizing radiation.

Authors:  D M Kambach; V L Sodi; P I Lelkes; J Azizkhan-Clifford; M J Reginato
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

Review 6.  Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases.

Authors:  Gary E L Brandt; Brian S J Blagg
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

7.  Late toxicity in long-term survivors from a phase 2 study of concurrent radiation therapy, temozolomide and valproic acid for newly diagnosed glioblastoma.

Authors:  Andra V Krauze; Megan Mackey; Lindsay Rowe; Michal G Chang; Diane J Holdford; Theresa Cooley; Joanna Shih; Philip J Tofilon; Kevin Camphausen
Journal:  Neurooncol Pract       Date:  2018-04-16

8.  Dynamics of p53 and NF-κB regulation in response to DNA damage and identification of target proteins suitable for therapeutic intervention.

Authors:  Rainer Poltz; Michael Naumann
Journal:  BMC Syst Biol       Date:  2012-09-15

Review 9.  Preclinical models in radiation oncology.

Authors:  Jenna Kahn; Philip J Tofilon; Kevin Camphausen
Journal:  Radiat Oncol       Date:  2012-12-27       Impact factor: 3.481

Review 10.  Membrane-active host defense peptides--challenges and perspectives for the development of novel anticancer drugs.

Authors:  Sabrina Riedl; Dagmar Zweytick; Karl Lohner
Journal:  Chem Phys Lipids       Date:  2011-09-16       Impact factor: 3.329
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.